Xenetic Biosciences Inc. (NASDAQ: XBIO) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT XENETIC BIOSCIENCES INC.

Xenetic Biosciences Inc. (NASDAQ: XBIO)
Listen to this Section


$3.42
+0.0350 ( +1.04% ) 12.6K

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.

Market Data


Open $3.42
Previous Close $3.38
Volume 12.6K
Market Cap $7.74M
Day Range $3.14 - $3.44
52 Week Range $1.90 - $13.93
Shares Outstanding 2.29M
Change % +1.04%
Net Change ▲ 0.0350
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2012
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -77,500.00

Date Type Amount Purchased Purchaser
2024-06-21 Sale -20000.00 PARSLOW JAMES F
2023-12-18 Sale -2500.00 Mizrahy Moshe
2023-12-13 Sale -10000.00 PARSLOW JAMES F
2023-12-13 Sale -10000.00 Lockshin Curtis
2023-12-13 Sale -20000.00 EISENBERG JEFFREY F
2023-12-08 Sale -2500.00 Kornberg Roger D.
2023-12-08 Sale -2500.00 Callaway James Eric
2023-12-08 Sale -2500.00 VINOGRADOV ALEXEY ANDREEVICH
2023-12-08 Sale -2500.00 Dastoor Firdaus J.
2023-12-08 Sale -2500.00 Borisenko Grigory G.

SEC Filings


Form Type Description Pages Date
8-k 8K-related 14 Nov 13, 2025
10-q Quarterly Reports 44 Nov 12, 2025
def Proxies and info statements 18 Oct 31, 2025
ars Annual reports 1 Oct 31, 2025
8-k 8K-related 16 Oct 14, 2025
8-k 8K-related 14 Aug 13, 2025
10-q Quarterly Reports 44 Aug 12, 2025

Latest News


× Before browsing our site, please accept our cookies policy